Lyso-thermosensitive liposomal doxorubicin: an adjuvant to increase the cure rate of radiofrequency ablation in liver cancer
RTP Poon, N Borys - Future Oncology, 2011 - Taylor & Francis
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer death worldwide. No
more than 30% of HCC patients are considered suitable for curative treatment because of …
more than 30% of HCC patients are considered suitable for curative treatment because of …
Lyso-thermosensitive liposomal doxorubicin: an adjuvant to increase the cure rate of radiofrequency ablation in liver cancer.
RT Poon, N Borys - Future Oncology (London, England), 2011 - europepmc.org
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer death worldwide. No
more than 30% of HCC patients are considered suitable for curative treatment because of …
more than 30% of HCC patients are considered suitable for curative treatment because of …
Lyso-thermosensitive liposomal doxorubicin: An adjuvant to increase the cure rate of radiofrequency ablation in liver cancer
RTP Poon, N Borys - Future Oncology, 2011 - hub.hku.hk
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer death worldwide. No
more than 30% of HCC patients are considered suitable for curative treatment because of …
more than 30% of HCC patients are considered suitable for curative treatment because of …
[PDF][PDF] g Eva lu
RTP Poon, N Borys - Future Oncol, 2011 - websitearea3.brandinstitute.com
Rationale A review of 13 published trials of single-agent doxorubicin among 644 HCC
patients found an objective response rate of 19% and median overall survival of 4 months …
patients found an objective response rate of 19% and median overall survival of 4 months …
Lyso-thermosensitive liposomal doxorubicin: an adjuvant to increase the cure rate of radiofrequency ablation in liver cancer
RT Poon, N Borys - Future oncology (London, England), 2011 - pubmed.ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer death worldwide. No
more than 30% of HCC patients are considered suitable for curative treatment because of …
more than 30% of HCC patients are considered suitable for curative treatment because of …
Lyso-thermosensitive liposomal doxorubicin: an adjuvant to increase the cure rate of radiofrequency ablation in liver cancer
RTP Poon, N Borys - Future Oncology, 2011 - search.proquest.com
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer death worldwide. No
more than 30% of HCC patients are considered suitable for curative treatment because of …
more than 30% of HCC patients are considered suitable for curative treatment because of …
Lyso-thermosensitive liposomal doxorubicin: an adjuvant to increase the cure rate of radiofrequency ablation in liver cancer
RTP Poon, N Borys - Future Oncology, 2011 - cir.nii.ac.jp
抄録< jats: p> Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer death
worldwide. No more than 30% of HCC patients are considered suitable for curative …
worldwide. No more than 30% of HCC patients are considered suitable for curative …